Liquid nitrogen-treated autograft combined with megaprosthesis versus total femoral replacement for large-volume malignant femoral bone tumors: a comparative study.
In a retrospective cohort of 28 patients aged 8–24 years with malignant femoral bone tumors, liquid nitrogen-treated autograft plus megaprosthesis was associated with better functional scores, shorter operations, lower blood loss, and 70% bone union compared with total femoral replacement, while oncological differences were not statistically conclusive.
Open original publication →What the AI sees
In a retrospective cohort of 28 patients aged 8–24 years with malignant femoral bone tumors, liquid nitrogen-treated autograft plus megaprosthesis was associated with better functional scores, shorter operations, lower blood loss, and 70% bone union compared with total femoral replacement, while oncological differences were not statistically conclusive.
Research significance
The study provides preliminary clinical evidence that LN-MP can enable joint-preserving limb reconstruction with favorable function and feasible graft-host union; it remains an inference, requiring larger and longer controlled studies, that this approach improves long-term oncological or reconstructive outcomes over total femoral replacement.
Source abstract
BACKGROUND: Limb-salvage surgery for extensive femoral osteosarcoma presents major reconstructive challenges. Conventional options such as total femoral replacement (TFR) and long-segment biological reconstructions are associated with significant complications. We evaluated the clinical outcomes of a novel hybrid approach combining a liquid nitrogen-treated autograft with a megaprosthesis (LN-MP) and compared them with those of TFR. MATERIALS AND METHODS: This retrospective study included 28 patients (range 8-24 years old) with malignant femoral bone tumors treated between 2020 and 2024. Patients underwent either LN-MP (n = 10) or TFR (n = 18). Perioperative outcomes, functional results (Musculoskeletal Tumor Society score-MSTS), bone union, oncological control, and survival were analyzed. RESULTS: LN-MP demonstrated better functional outcomes (MSTS 27.0 ± 2.1 vs. 24.4 ± 2.2, p = 0.014), shorter operative time, and lower blood loss compared with TFR. Length of stay and follow-up duration were comparable. Continuous disease-free survival was higher in the LN-MP group (90% vs. 44%, p = 0.058), with lower recurrence (10% vs. 28%). Bone union was achieved in 70% of LN-MP cases at a mean of 9 months, with longer graft length associated with delayed union. CONCLUSIONS: LN-MP reconstruction may serve as a joint-preserving alternative to total femoral replacement for patients with extensive malignant femoral tumors. In this preliminary series, LN-MP was associated with favorable functional outcomes, satisfactory graft-host bone union, and acceptable oncological results. Given the retrospective design, limited sample size, and short follow-up duration, further studies with larger cohorts and longer follow-up are required to define the role of LN-MP among contemporary limb-salvage reconstructive strategies. LEVEL OF EVIDENCE: Therapeutic, Level III: retrospective comparative cohort study.